Redeye acknowledges a milestone with the first patient recruited in China in Calliditas pivotal phase III trial with Nefecon. We believe this quick initiation of patient enrolment in China increases the probability that the Chinese patient sample in part B of the trial will be sufficient to form the basis for market approval in China. If Calliditas manages to adhere to its timeline of a fully recruited trial by 2022, we see good prospects that a market launch in China could be possible in late 2023/early 2024 (our current estimates assume sales starting from 2024) – contingent on encouraging data, of course.